Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
27 Fevereiro 2023 - 9:30AM
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company,
formerly KemPharm, Inc.), a rare disease therapeutics company, has
announced that the Company will host a conference call and live
audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to
discuss its corporate and financial results for the fourth quarter
and full-year 2022.
The audio webcast with a slide presentation will
be accessible via the Investor Relations section of the Company’s
website, http://investors.zevra.com/. An archive of the webcast and
presentation will be available for 90 days beginning at
approximately 9:30 a.m. ET, on March 7, 2023.
Additionally, interested participants and investors may access
the conference call by dialing either:
- (800) 343-4849
(U.S.)
- +1 (203) 518-9848
(International)
- Conference ID:
ZVRAQ422
About Zevra
Zevra Therapeutics is a rare disease company
melding science, data, and patient need to create transformational
therapies for diseases with limited or no treatment options. With
unique, data-driven clinical, regulatory, and commercialization
strategies, the Company is overcoming complex drug development
challenges to bring much-needed therapies to patients.
Contacts
Nichol Ochsner+1 (732) 754-2545nochsner@zevra.com
Jennifer Arcure+1 (917)
603-0681Jennifer.arcure@evokegroup.com
KemPharm (NASDAQ:KMPH)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
KemPharm (NASDAQ:KMPH)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025